Clinical Trials Logo

Clinical Trial Summary

This project will evaluate the effect of gender-affirming testosterone treatment on how other medications are processed by the body.


Clinical Trial Description

Gender-affirming hormone therapy may include testosterone, a hormone that the body creates and uses naturally. Testosterone is prepared as a medication that patients may take to increase hormone levels. Changes in testosterone concentrations in the body may affect how the body processes other medicines. The purpose of this study is to find out how testosterone therapy affects a single tracer dose of approved medicines in the blood (midazolam, digoxin, and acetaminophen) and to confirm testosterone treatment does not affect natural bacterial in the gut. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05116293
Study type Observational
Source University of Washington
Contact Lauren Cirrincione, MPH, PharmD
Phone 650-353-7782
Email [email protected]
Status Recruiting
Phase
Start date May 1, 2021
Completion date June 1, 2022

See also
  Status Clinical Trial Phase
Completed NCT04036500 - Transgender Estradiol Early Phase 1
Recruiting NCT04534881 - Effect of Progesterone on Testosterone Concentrations and Breast Development in Transwomen Phase 2
Completed NCT04448418 - The Impact of COVID-19 Outbreak on Trans-population's Health in Italy
Recruiting NCT04515472 - Effect of Gender Affirming Hormone Therapy on Glucose Metabolism Early Phase 1
Active, not recruiting NCT03864913 - Comparing Subcutaneous Testosterone to Intramuscular Testosterone in Gender Affirming Care of Transgender Male Adolescents Early Phase 1
Completed NCT03120936 - The Stay Study: A Demonstration Project Advancing PrEP Delivery in the San Francisco Bay Area Transgender Community Phase 4
Recruiting NCT04478760 - Trans & Non-binary Reference Intervals While on Hormone Therapy Study